Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease Ezequiel Ridruejo, Rebeca Garcia-Agudo, Manuel Mendizabal, Sami Aoufi-Rabih, Vivek Dixit, Marcelo Silva, Fabrizio Fabrizi

Sofosbuvir-based regimens for HCV in stage 4–stage 5 chronic kidney disease. A systematic review with meta-analysis Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit, Ezequiel Ridruejo

The impact of antiviral therapy for HCV on kidney disease: a systematic review and meta-analysis Fabrizio Fabrizi, Roberta Cerutti, Vivek Dixit, Piergiorgio Messa